Brompheniramine

Oral
Allergic conditions

May be taken with or without food. May be taken w/ food or milk to reduce GI discomfort.

Incompatible w/ some amidotrizoate, adipiodone and iotalamate salts.

Pregnancy (3rd trimester).

Patient w/ glaucoma, prostatic hyperplasia, genitourinary obstruction, asthma, chronic bronchitis, thyroid dysfunction, CV disease (e.g. HTN, ischaemic heart disease). Childn. Pregnancy and lactation.

Excitability (esp in childn), drowsiness, sedation, angina pectoris, chest tightness, circulatory shock, extrasystoles, hypotension, palpitation, increased BP, tachycardia, anxiety, ataxia, chills, confusion, euphoria, fatigue, headache, hysteria, insomnia, irritability, nervousness, neuritis, paraesthesia, restlessness, seizure, tension, vertigo, diaphoresis, photosensitivity, rash, urticaria, abdominal cramps, anorexia, constipation, diarrhoea, epigastric distress, heartburn, nausea, vomiting, xerostomia, dysuria, early menstruation, urinary retention, agranulocytosis, haemolytic anaemia, thrombocytopenia, tremor, weakness, diplopia, mydriasis, blurred vision, acute labyrinthitis, tinnitus, polyuria, dry nose or throat, nasal congestion, bronchial secretions, wheezing.

This drug may cause drowsiness and sedation, if affected, do not drive or operate machinery.

May enhance the sedative effects of CNS depressants (e.g. barbiturates, anxiolytics, hypnotics, opioid analgesics, antipsychotics). Additive antimuscarinic effects w/ other antimuscarinic drugs (e.g. atropine, TCAs, MAOIs). May mask the warning signs of damage caused by ototoxic drugs (e.g. aminoglycosides).

May enhance the CNS depressant effects of alcohol.

May cause false-positive result w/ urine detection of amphetamine/methamphetamine. May interfere w/ skin tests using allergen extracts.

Description: Brompheniramine is an antihistamine w/ antimuscarinic and moderate sedative actions. It competes w/ histamine for H₁-receptor sites on effector cells.
Pharmacokinetics:
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 2-4 hr.
Distribution: Widely distributed. Volume of distribution: Approx 12 L/kg. Plasma protein binding: 39-49%.
Metabolism: Undergoes N-dealkylation to form monodesmethylbrompheniramine and didesmethylbrompheniramine, and is metabolised to propionic acid derivative.
Excretion: Via urine (approx 40%, as unchanged drug and metabolites) and faeces (approx 2%). Elimination half-life: Approx 25 hr.

Source: National Center for Biotechnology Information. PubChem Database. Brompheniramine, CID=6834, https://pubchem.ncbi.nlm.nih.gov/compound/Brompheniramine (accessed on Jan. 22, 2020)

Store between 15-30°C. Protect from light.

Antihistamines & Antiallergics

R06AB01 - brompheniramine ; Belongs to the class of substituted alkylamines used as systemic antihistamines.

Anon. Brompheniramine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 23/08/2016.

Buckingham R (ed). Brompheniramine maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 23/08/2016.

Buckingham R (ed). Interactions of Antihistamines . Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 23/09/2016 .

J-TAN PD Liquid (JayMac Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 23/08/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Brompheniramine Maleate, Dexbrompheniramine Maleate . AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 23/08/2016.